Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

INF 108

Next Previous
Drug Profile

INF 108

Alternative Names: INF-108

Latest Information Update: 04 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Infinant Health
  • Class Bacteria
  • Mechanism of Action Gastrointestinal microbiome modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Necrotising enterocolitis
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Necrotising enterocolitis

Most Recent Events

  • 19 May 2025 Infinant Health has patent protection for "Methods for treating enteric injury" in the multiple countries worldwide
  • 07 May 2025 Preclinical studies in Necrotising enterocolitis (Prevention) in USA (unspecified route) prior to May 2025
  • 07 May 2025 INF 108 receives Orphan Drug status for Necrotising enterocolitis (In infants, In neonates, Prevention) in USA

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top